1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag

Senzime announces full subscription of directed share issue

MAR

Senzime AB (publ) (“Senzime” or the “Company”) announced on 24 August 2023 the board of directors’ resolution to carry out a directed share issue of approximately MSEK 56, at current market price. Chairman of the board, Adam Dahlberg, participated in the rights issue, which was subject to approval from the general meeting. Subscription of 1,137,500 shares has now been made and the directed share issue of approximately MSEK 56 is therefore fully subscribed.

The subscription of shares in the directed issue of shares to the Company’s chairman of the board, Adam Dahlberg, lasted until 21 September 2023 and has now concluded. The rights issue was fully subscribed, resulting in the Company raising approximately MSEK 5.1. The subscription price in the directed issue of shares was SEK 4.50 per share, which is the same subscription price as the issue of shares which was resolved and announced on 24 August 2023.

The directed issue of shares results in an increase in the number of shares in the Company by 1,137,500 shares from 98,985,114 to 100,122,614. The share capital of the Company increases by SEK 142,187.50, from SEK 12,373,139.25 to SEK 12,515,326.75. Consequently, the new issue of shares leads to a dilution of approximately 1.1% based on the total number of shares in the Company after the rights issue."

Advisers

In connection with the Share Issue, the Company has retained Zonda Partners as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
 
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-22 13:00 CEST.

Attachments

Senzime announces full subscription of directed share issue

Datum 2023-09-22, kl 13:00
Källa MFN
Bifogade filer
Senzime announces full subscription of directed share issue
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!